Xiaojun Xu

5.3k citations
94 papers · 2.8k indexed · 3 hit papers · h-index 22

Xiaojun Xu

89 papers receiving 2.8k citations

Hit Papers

The Immune Epitope Database and Analys...3602006202620122019100200300400500

Peers

Xiaojun Xu
Comparison fields: 5 of 151
  • Infectious Diseases 755
  • Molecular Biology 1.5k
  • Oncology 424
  • Neurology 220
  • Immunology 236
Replace Tina Izard with:
Tina Izard United States
Marc De Maeyer Belgium
Alan Norris United Kingdom
Torsten Steinmetzer Germany
Jiannan Feng China
Daniel Hoffmann Germany
Sheng‐You Huang China
Nicole Zitzmann United Kingdom
Steven K. Drake United States
Guangdi Li China
Xiaojun Xu relative to Tina Izard United States Tina Izard's profile →
Citations per field
00.5×1.5×2.4×
Tina Izard · 1×
Citations per year

Countries citing papers authored by Xiaojun Xu

Since Specialization
Citations

This map shows the geographic impact of Xiaojun Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojun Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojun Xu more than expected).

Fields of papers citing papers by Xiaojun Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojun Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojun Xu. The network helps show where Xiaojun Xu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xiaojun Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xiaojun Xu Line = papers co-authored together Xiaojun Xu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20250
3 20252
4 202418
5 20241
6 20242
7 20230
8 20232
9 20237
10 20234
11 20224
12 202210
13 202117
14 202111
15 202016
16 20195
17 20192
18 20195
19
Can you fool AI with adversarial examples on a visual Turing test
201713
20 201534

About Xiaojun Xu

Xiaojun Xu is a scholar working on Computational Theory and Mathematics, Molecular Biology and Virology, having authored 94 papers that have together received 2.8k indexed citations. Recurring topics across this work include RNA and protein synthesis mechanisms (33 papers), RNA Research and Splicing (25 papers), RNA modifications and cancer (19 papers), Computational Drug Discovery Methods (14 papers), DNA and Nucleic Acid Chemistry (11 papers), Protein Structure and Dynamics (10 papers), RNA Interference and Gene Delivery (7 papers) and Nanopore and Nanochannel Transport Studies (7 papers). The work is most often cited by research in Infectious Diseases (755 citations), Molecular Biology (1.5k citations) and Oncology (424 citations). Xiaojun Xu has collaborated with scholars based in China, United States and India. Frequent co-authors include Shi‐Jie Chen, Zhe‐Sheng Chen, Kun Zhao, Han Zhang, Yehuda G. Assaraf, Wen Li, Dong‐Hua Yang, Jinbing Xie, Bjoern Peters and Alessandro Sette. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026